1. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy
- Author
-
Eve H. Pickering, Keith Kobylarz, Jianqing Chen, Jonathan Golas, Ohad Ilovich, Lindsay King, Sripad Ram, Kevin P. Maresca, Timothy J. McCarthy, Laigao Chen, James S. Hardwick, Amira Hussein, Jatin Narula, Edward Rosfjord, Anand Giddabasappa, Edmund J. Keliher, Ian D. Wilson, Adam Root, David Schaer, Divya Mathur, Paul A. Rejto, and Kevin Staton
- Subjects
Cancer Research ,Adoptive cell transfer ,T cell ,T-Lymphocytes ,89Zr-IAB22M2C PET imaging ,Receptors, Enterotoxin ,Standardized uptake value ,Mice, SCID ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Cell Line, Tumor ,Positron Emission Tomography Computed Tomography ,medicine ,Cytotoxic T cell ,Animals ,Radiology, Nuclear Medicine and imaging ,030304 developmental biology ,0303 health sciences ,business.industry ,GUCY2C bispecific antibody ,Immuno-oncology ,Imaging agent ,medicine.anatomical_structure ,Oncology ,CD8 T cell ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Cancer research ,Zirconium ,business ,Preclinical imaging ,Ex vivo ,CD8 ,Biomarkers ,Research Article - Abstract
Purpose A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging bispecific antibody that binds to CD3 and guanylyl cyclase C, a protein that is over-expressed by colorectal cancers. Here, we used 89Zr-Df-IAB22M2C (89Zr-Df-Crefmirlimab), a human CD8-specific minibody to monitor CD8+ T cell infiltration into tumors by positron emission tomography. We investigated the ability of 89Zr-Df-IAB22M2C to track anti-tumor activity induced by PF-07062119 in a human CRC adoptive transfer mouse model (with injected activated/expanded human T cells), as well as the correlation of tumor radiotracer uptake with CD8+ immunohistochemical staining. Procedures NOD SCID gamma mice bearing human CRC LS1034 tumors were treated with four different doses of PF-07062119, or a non-targeted CD3 BsAb control, and imaged with 89Zr-Df-IAB22M2C PET at days 4 and 9. Following PET/CT imaging, mice were euthanized and dissected for ex vivo distribution analysis of 89Zr-Df-IAB22M2C in tissues on days 4 and 9, with additional data collected on day 6 (supplementary). Data were analyzed and reported as standard uptake value and %ID/g for in vivo imaging and ex vivo tissue distribution. In addition, tumor tissues were evaluated by immunohistochemistry for CD8+ T cells. Results The results demonstrated substantial mean uptake of 89Zr-Df-IAB22M2C (%ID/g) in PF-07062119-treated tumors, with significant increases in comparison to non-targeted BsAb-treated controls, as well as PF-07062119 dose-dependent responses over time of treatment. A moderate correlation was observed between tumor tissue radioactivity uptake and CD8+ cell density, demonstrating the value of the imaging agent for non-invasive assessment of intra-tumoral CD8+ T cells and the mechanism of action for PF-07062119. Conclusion Immune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of 89Zr-IAB22M2C PET to evaluate PD responses (mice) to a novel immunotherapeutic.
- Published
- 2021